tradingkey.logo

BRIEF-FDA Issues Class-Wide Labeling Changes For Testosterone Products

ReutersFeb 28, 2025 8:01 PM

- FDA:

  • FDA ISSUES CLASS-WIDE LABELING CHANGES FOR TESTOSTERONE PRODUCTS

  • FDA: RECOMMENDING CHANGES TO CURRENT LABELING LANGUAGE TO INCLUDE ADDING RESULTS OF TRAVERSE TRIAL TO ALL TESTOSTERONE PRODUCTS

  • FDA: RECOMMENDS REMOVING LANGUAGE FROM BOXED WARNING RELATED TO INCREASED RISK OF ADVERSE CARDIOVASCULAR OUTCOMES FOR ALL TESTOSTERONE PRODUCTS

  • FDA: RECOMMENDS TO ADD WARNING ABOUT INCREASED BLOOD PRESSURE FOR TESTOSTERONE PRODUCTS WHICH DO NOT HAVE SUCH WARNING IN THEIR LABELING

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI